PLIANT THERAPEUTICS, INC. current report, 28 September 2023

Pliant Therapeutics, Inc. — Form 8-K Summary

Report date: September 28, 2023; filed October 3, 2023. The filing reports material real estate lease transactions and a related direct financial obligation. It does not provide operating results for a reporting period.

Business Context and Material Agreements

  • On September 28, 2023, Pliant entered into a lease with HCP BTC, LLC for approximately 100,904 rentable square feet at 331 Oyster Point Boulevard, South San Francisco, California.
  • The premises are intended for laboratory and office use. The initial lease term is approximately seven years and is expected to begin when the landlord substantially completes tenant improvements.
  • Pliant may occupy completed office space before the full lease commencement date.
  • The lease includes an eight-year extension option at then-current market rates and a right of first offer on remaining space at the property.

Financial Obligations and Liquidity

ItemTerms disclosed
Base rentApproximately $0.26 million per month in the first year, reflecting an initial phase-in, increasing annually to approximately $0.71 million per month in the final year of the initial term.
Operating expensesPliant is responsible for operating expenses related to the Oyster Point premises.
Letter of credit$1.43 million required in connection with the Oyster Point lease.
Lease termApproximately seven years, with an optional eight-year extension.

The filing does not provide revenue, profit, cash flow, margin, debt-balance, cash-balance, or other broader liquidity metrics. The lease creates a direct financial obligation, with total undiscounted payments not stated in the filing text provided.

Changes Versus Prior Arrangements

  • In connection with the Oyster Point lease, Pliant entered into a termination agreement for its existing lease at 260 Littlefield Avenue, South San Francisco.
  • The Littlefield lease, previously expected to expire June 30, 2025, will terminate 60 days after the Oyster Point lease commencement date.
  • Pliant must vacate and deliver exclusive possession of the Littlefield premises by the termination date.
  • Pliant will have no further obligation to pay rent or its share of direct expenses from and after the Oyster Point lease commencement date.
  • No early termination penalty is required under the termination agreement.

Outlook, Risks, and Unusual Items

  • The timing of lease commencement depends on completion of tenant improvements and is not specified as a calendar date.
  • Rent will escalate materially over the initial term, and operating expenses are additional obligations.
  • The required $1.43 million letter of credit may affect available liquidity, although the filing does not state its funding source or impact on cash.
  • The filing does not provide management guidance or commentary regarding the financial impact of the relocation.
  • The lease and termination agreement contain additional terms and omitted schedules or exhibits; investors should review the filed agreements for complete obligations and conditions.

Key Facts for Investors to Verify

  • Actual Oyster Point lease commencement date and timing of tenant-improvement completion.
  • Accounting treatment, recognized lease liabilities, and future minimum lease payments in subsequent financial statements.
  • Source and collateral requirements for the $1.43 million letter of credit.
  • Actual operating expenses, rent escalators, and any additional tenant-improvement or relocation costs.
  • Completion of the Littlefield premises turnover and cessation of related rent and expense obligations.